Get the Stockscreener App
1.88
6.82%
0.12
After Hours:
1.87
-0.010
-0.53%
Invivyd Inc stock is traded at $1.88, with a volume of 5.36M.
It is up +6.82% in the last 24 hours and up +31.47% over the past month.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
See More
Previous Close:
$1.76
Open:
$1.75
24h Volume:
5.36M
Relative Volume:
0.89
Market Cap:
$225.87M
Revenue:
-
Net Income/Loss:
$-225.14M
P/E Ratio:
-0.9592
EPS:
-1.96
Net Cash Flow:
$-192.27M
1W Performance:
+32.39%
1M Performance:
+31.47%
6M Performance:
+242.44%
1Y Performance:
+84.31%
1-Day Range:
$1.64
$1.90
1-Week Range:
$1.34
$2.01
52-Week Range:
$0.3546
$2.74
Invivyd Inc Stock (IVVD) Company Profile
Name
Invivyd Inc
Sector
Industry
Phone
(781) 819-0080
Address
1601 TRAPELO ROAD, WALTHAM
Compare IVVD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IVVD
Invivyd Inc
|
1.88 | 377.36M | 0 | -225.14M | -192.27M | -1.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Invivyd Inc Stock (IVVD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-05-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-26-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-01-23 | Initiated | H.C. Wainwright | Buy |
Invivyd Inc Stock (IVVD) Latest News
Using Python tools to backtest Invivyd Inc. strategies2025 Top Decliners & Low Risk Growth Stock Ideas - newser.com
How to forecast Invivyd Inc. trends using time seriesJuly 2025 Update & AI Forecasted Entry/Exit Points - newser.com
Candlestick signals on Invivyd Inc. stock todayMarket Growth Report & Fast Moving Stock Trade Plans - newser.com
Will Invivyd Inc. stock gain from strong economyPortfolio Risk Summary & Growth Focused Stock Reports - newser.com
What’s the recovery path for long term holders of Invivyd Inc.Weekly Stock Analysis & Weekly Top Gainers Trade List - newser.com
What Fibonacci levels say about Invivyd Inc. reboundWeekly Gains Report & Free Fast Gain Swing Trade Alerts - newser.com
Is Invivyd Inc. stock in correction or buying zoneAnalyst Downgrade & Entry Point Confirmation Signals - newser.com
Can a trend reversal in Invivyd Inc. lead to recovery2025 Growth vs Value & Fast Exit and Entry Strategy Plans - newser.com
How to use Fibonacci retracement on Invivyd Inc.Market Growth Review & Free Community Consensus Stock Picks - newser.com
Cantor Fitzgerald Estimates Invivyd FY2025 Earnings - MarketBeat
Detecting support and resistance levels for Invivyd Inc.Quarterly Portfolio Review & Reliable Volume Spike Trade Alerts - newser.com
How supply chain issues affect Invivyd Inc. stockInsider Buying & Accurate Entry/Exit Alerts - newser.com
Ranking Invivyd Inc. among high performing stocks via toolsEarnings Risk Summary & Weekly Setup with High ROI Potential - newser.com
A Look at Invivyd’s (IVVD) Valuation Following FDA Clearance for Late-Stage COVID-19 Antibody Trial - simplywall.st
What candlestick patterns are forming on Invivyd Inc.July 2025 Momentum & Short-Term High Return Strategies - newser.com
Invivyd (IVVD) Is Up 34.4% After FDA Clears Late-Stage COVID Antibody Program—What’s Changed - Yahoo Finance
Invivyd (NASDAQ:IVVD) Receives "Sell (D-)" Rating from Weiss Ratings - MarketBeat
When is the best time to exit Invivyd Inc.Weekly Profit Analysis & Free Weekly Chart Analysis and Trade Guides - newser.com
Can Invivyd Inc. rally from current levelsPortfolio Gains Summary & Expert Approved Momentum Ideas - newser.com
Multi asset correlation models including Invivyd Inc.2025 Macro Impact & Weekly Watchlist for Consistent Profits - newser.com
Are Investors Undervaluing Invivyd, Inc. (NASDAQ:IVVD) By 31%? - 富途牛牛
Invivyd (IVVD) Is Up 26.8% After FDA Clears Phase 3 Trials for COVID Antibody Candidate - simplywall.st
Invivyd (IVVD): Assessing Valuation After FDA Clears Phase 3 COVID-19 Antibody Trial - Yahoo Finance
D. Boral Capital Maintains Invivyd (IVVD) Buy Recommendation - Nasdaq
Invivyd receives FDA clearance for COVID antibody prevention trials By Investing.com - Investing.com Nigeria
D. Boral Capital Increases Invivyd (NASDAQ:IVVD) Price Target to $2.00 - MarketBeat
Invivyd, Inc. Announces U.S. Food and Drug Administration Clearance of Investigational New Drug Application and Provide Feedback to Advance the Company's Revolation Clinical Program - MarketScreener
New Haven biotech advances vaccine-alternative to prevent COVID - Hartford Business Journal
Invivyd stock soars after FDA clears IND for COVID antibody candidate - Investing.com
Cantor Fitzgerald Initiates Invivyd at Overweight With $10 Price Target - MarketScreener
This Commerce Bancshares Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Invivyd Shares Climb After FDA Advances Its Covid-Preventing Drug - MarketScreener
Invivyd, Inc. (NASDAQ:IVVD) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Invivyd (NASDAQ:IVVD) Now Covered by Cantor Fitzgerald - MarketBeat
Invivyd announces IND clearance, alignment with FDA on VYD2311 program - TipRanks
Invivyd’s VYD2311 Receives FDA Clearance for Trials - TipRanks
Invivyd receives FDA clearance for COVID antibody prevention trials - Investing.com
Invivyd gets FDA nod to start key trial of COVID-blocking antibody VYD2311 - MarketScreener
Invivyd Announces U.S. IND Clearance and Alignment with U.S. FDA on Pivotal Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID - The Manila Times
Invivyd Announces Upcoming Phase 3 Clinical Trials for VYD2311, a Novel COVID Prevention Therapy - Quiver Quantitative
What to do if you’re stuck in Invivyd Inc.Exit Point & Fast Exit and Entry Trade Guides - newser.com
Earnings visualization tools for Invivyd Inc.July 2025 Intraday Action & Daily Profit Focused Screening - newser.com
How Invivyd Inc. stock performs in interest rate cyclesGap Down & Weekly Return Optimization Plans - newser.com
Why retail investors pile into Invivyd Inc. stockJuly 2025 Outlook & Precise Trade Entry Recommendations - newser.com
How moving averages guide Invivyd Inc. tradingPortfolio Performance Summary & Fast Moving Stock Trade Plans - newser.com
Is Invivyd Inc. stock safe for conservative investorsWeekly Investment Report & Fast Momentum Entry Tips - newser.com
Applying chart zones and confluence areas to Invivyd Inc.2025 Investor Takeaways & Long-Term Safe Investment Plans - newser.com
Invivyd Inc Stock (IVVD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):